|
|
|
02.07.26 - 10:48
|
European Champions: ASML, Novo und GSK sorgen für Schwung (Der Aktionaer)
|
|
|
In einer volatilen Börsenphase hat sich der European Champions Index sehr robust entwickelt und steht nun kurz vor einem neuen Allzeithoch. Wesentliche Erfolgsfaktoren sind die defensive Aufstellung und die Branchenstreuung. Mit Novo Nordisk, Novartis, Astrazeneca, GSK, Roche und Sanofi entfällt rund die Hälfte der Aktien auf den Gesundheitssektor....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.07.26 - 08:45
|
AstraZeneca Buy (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Astrazeneca von 16525 auf 16370 Pence gesenkt, aber die Einstufung auf "Buy" belassen. Für das zweite Quartal sieht Analyst Rajan Sharma seine Prognosen etwas unter ......
|
|
|
|
|
30.06.26 - 10:48
|
AstraZeneca Sell (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Astrazeneca mit einem Kursziel von 11500 Pence belassen. Efzimfotase sei zwar nicht der wichtigste Baustein in der Pipeline des Pharmakonzerns, spiele aber eine wichtige Rolle als Option für das ......
|
|
|
30.06.26 - 08:03
|
AstraZeneca Overweight (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca mit einem Kursziel von 16000 Pence auf "Overweight" belassen. Analyst Richard Vosser erwartet von den Briten eine erneut starke Umsatzentwicklung, wie er am Dienstag ......
|
|
|
|
|
|
|
|
|
29.06.26 - 08:42
|
Enhertu approved in EU for HER2+ solid tumours (Cision)
|
|
|
29 June 2026
Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours
Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which demonstrated clinically meaningful responses across a broad range of tumours
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC]...
|
|
|
29.06.26 - 08:06
|
Datroway recommended for approval in EU for TNBC (Cision)
|
|
|
29 June 2026
Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
Recommendation based on TROPION-Breast02 Phase III trial where AstraZeneca and Daiichi Sankyo's Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival
If approved, Datroway has the potential to be the first TROP2-directed antibody drug conjugate for patients in the EU with a...
|
|
|
|
|
26.06.26 - 08:06
|
AstraZeneca Buy (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca mit einem Kursziel von 18000 Pence auf "Buy" belassen. Die anstehenden Phase-III-Daten der Studie gegen ATTR-Kardiomyopathie könnten zum Kurstreiber für die Briten ......
|
|
|
|
|
22.06.26 - 15:06
|
Within3 Appoints Erin Mistry as Chief Executive Officer (Business Wire)
|
|
|
Global biopharma executive and commercial strategist to lead the company's next chapter of growthCLEVELAND--(BUSINESS WIRE)--#AI--Within3, the leading Launch Intelligence™ platform for life sciences, today announced the appointment of Erin Mistry as Chief Executive Officer. Mistry brings more than 20 years of experience in global biopharma commercialization, having launched and priced more than 20 pharmaceutical products across eight therapeutic areas.
Most recently, Mistry served as Chief Commercial Officer at CorMedix, where she led the launch of DefenCath and drove the company to break-even within six months and profitability in under a year. Earlier, she held senior global leadership roles at Syneos Health and Jupiter Life Sciences, as well as industry roles at MedImmune and AstraZeneca. She serves on the Executive Policy Council at the Harvard T.H. Chan School of Public Health and is a member of the Pharma AI Council.
Jason Smith, Within3's Chief Technology Officer, said: “Erin has spent her ca...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
